Skip to main content
TYK Medicines, Inc logo

TYK Medicines, Inc — Investor Relations & Filings

Ticker · 2410 ISIN · CNE100006L34 HKEX Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2024-08-12 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2410

About TYK Medicines, Inc

https://www.tykmedicines.com

TYK Medicines, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative small-molecule targeted therapies. The company leverages a proprietary small molecule drug design and screening platform, with a primary strategic focus on oncology, particularly treatments for lung cancer. The lead pipeline asset, TY-9591 (Edotamidine mesylate), an EGFR-targeted therapy, is currently in the Pre-NDA stage, having demonstrated promising clinical efficacy in treating lung cancer patients with brain metastasis. The pipeline also includes assets such as TY-302 and TY-2136, alongside multiple CDK inhibitors in clinical development, reflecting a commitment to addressing unmet medical needs in targeted cancer treatment.

Recent filings

Filing Released Lang Actions
GLOBAL OFFERING
Regulatory Filings
2024-08-12 English
GLOBAL OFFERING
Capital/Financing Update Classification · 95% confidence The document is an announcement related to a Global Offering of shares by TYK Medicines, Inc. It includes detailed information about the offering structure, application process, pricing, and expected timetable. The text references the prospectus and provides instructions for investors on how to apply for shares. It is clearly an announcement about a capital raising event and share issuance, not a financial report, earnings release, or regulatory filing unrelated to capital changes. The document is lengthy (15,000 characters) and contains substantive details about the offering, which aligns with a Capital/Financing Update rather than a simple report publication or regulatory filing. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-08-12 English
INSIDE INFORMATION - EXPECTED DECREASE IN LOSS
Earnings Release Classification · 95% confidence The document is an announcement by Namyue Holdings Limited regarding an expected decrease in loss for the six months ended 30 June 2024. It is based on preliminary unaudited consolidated management accounts and explicitly states that the final interim results will be published later. The announcement is made pursuant to the Listing Rules and Inside Information Provisions, indicating it is a regulatory disclosure of inside information. The document does not contain actual financial statements or detailed financial analysis but provides a summary of expected financial performance. It is a typical earnings update or profit warning announcement rather than a full interim report. Given the nature of the announcement as a preliminary earnings update and inside information disclosure, it fits best under the category of Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights only. H1 2024
2024-08-09 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from Namyue Holdings Limited regarding the date of a board meeting to consider and approve the unaudited interim results for the six months ended 30 June 2024 and the possible payment of an interim dividend. It does not contain any financial data or detailed report content but merely informs about the upcoming board meeting and the agenda. The document length is only 1378 characters, which is quite short and fits the pattern of an announcement rather than a full interim report. According to the rules, such announcements about the timing of board meetings and report considerations are best classified as Regulatory Filings (RNS) because they do not contain the actual interim report or financial statements themselves.
2024-08-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 July 2024. It details movements in issued shares, treasury shares, share options, warrants, convertibles, and other agreements related to share issuance. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, focusing on share capital and share movements. It is not a full financial report, earnings release, or management discussion. It is a regulatory filing related to share capital movements but does not announce new share issues or capital changes per se, rather it reports monthly movements. Given the detailed nature and regulatory context, but not fitting other categories like SHA (Share Issue/Capital Change) which is for announcements, this fits best under Regulatory Filings (RNS) as a general regulatory announcement about share movements under exchange rules. The document length is under 5,000 characters, but it contains substantive data on share movements, so it is not merely an announcement of a report. Therefore, the best classification is Regulatory Filings (RNS).
2024-08-01 English
OC Announcement - Appointment
Regulatory Filings Classification · 95% confidence The document is an announcement related to the listing application of TYK Medicines, Inc on the Hong Kong Stock Exchange. It contains disclaimers about the offering, the status of the application, and the appointment of overall coordinators. It explicitly states that it is not a prospectus or offering document and that no investment decision should be based on this announcement. There are no financial statements, no detailed financial data, or report content. The document is informational and regulatory in nature, serving as a public disclosure about the listing process and coordinators. It is not a full report like an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is also not a proxy, voting result, or management change announcement. Given the nature and length (8274 characters) and the content, this fits best as a Regulatory Filing (RNS) because it is a regulatory announcement that does not fit other specific categories and is not a report itself but a regulatory disclosure about the listing process and coordinators.
2024-07-29 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.